Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.

NCT02260193 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT02260193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02260193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 10, 2014
Completion date
July 22, 2015
Enrollment
94 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, end stage renal disease